XSHE
300412
Market cap300mUSD
Jul 10, Last price
4.18CNY
1D
2.20%
1Q
-19.92%
Jan 2017
-56.28%
IPO
59.37%
Name
Zhejiang Canaan Technology Ltd
Chart & Performance
P/E
70.19
P/S
1.69
EPS
0.06
Div Yield, %
1.47%
Shrs. gr., 5y
1.56%
Rev. gr., 5y
3.05%
Revenues
1.23b
-10.98%
Net income
30m
-18.27%
CFO
190m
+59.06%
Dividend
Jun 05, 20250.06 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Canaan Technology Co., Ltd. is a Chinese enterprise specializing in the design, production, and sale of advanced pharmaceutical machinery. Its extensive product portfolio caters broadly to the pharmaceutical industry, particularly within the Oral Solid Dosage (OSD) segment. This includes essential equipment such as dispensing units, high shear mixers, roller compactors, fluid beds, mills, pelleting and coating machines, tablet presses, capsule fillers, and various associated components like pharma lifters, washing machines, and pharma bins. Beyond OSD, Canaan Technology also supplies specialized solutions including OEB equipment, isolators, machinery for research and development, API production systems, packaging solutions, water purification systems, extraction and reactor units, and warehouse logistics products. The company's core clientele operates within the pharmaceutical industry. Established in 2000, Zhejiang Canaan Technology maintains its corporate headquarters in Wenzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||